Brief CommunicationBrief Communication
Open Access

Real-world treatment patterns and clinical outcomes in patients with prostate cancer.

A single institution experience in Saudi Arabia

Ruba Abu Khizanah, Emad Tashkandi, Mohammad Jaffal, Mohammed Alsaedi, Yazan Al-ahmdi, Abdulmajeed Almehmadi and Khaled A. Elnaghi
Saudi Medical Journal June 2024, 45 (6) 639-642; DOI: https://doi.org/10.15537/smj.2024.45.6.20240042

Article Figures & Data

Tables

  • Table 1

    - Demographic and clinical characteristics.

    Variablesn (%)
    Age, median (min-max)70 (35-94)
    Nationality
    Saudi203 (72.0)
    Non-Saudi79 (28.0)
    BMI at initial diagnosis, median (min-max)26.30 (14.20-44)
    Presence of comorbidities
    Cardiovascular system38 (13.5)
    Hypertension164 (58.2)
    Diabetes mellitus125 (44.3)
    Performance status
    ≤2241 (85.5)
    335 (12.4)
    46 (2.1)
    Metastatic184 (65.2)
    Non metastatic98 (34.8)
    Gleason score at initial diagnosis
    ≤786 (30.5)
    ≥8196 (69.5)
    The metastatic site
    Bone147 (52.1)
    Visceral12 (4.9)
    Lymph node22 (7.8)
    None99 (35.1)

    • Values are presented as numbers and percentages (%).

    • min: minimum, max: maximum, BMI: body mass index

  • Table 2

    - Treatment characteristics.

    Variablesn (%)
    Surgery
    Radical retro pubic prostatectomy15 (5.3)
    Radical perineal prostatectomy2 (0.7)
    Transurethral resection of the prostate40 (14.2)
    Unmentioned27 (9.6)
    No surgery198 (70.2)
    Radiotherapy
    External beam radiotherapy97 (34.4)
    Brachytherapy1 (0.4)
    No radiotherapy184 (65.2)
    1st-line treatment
    ADT176 (62.4)
    ADT+bicalutamide27 (9.6)
    ADT+abiraterone23 (8.2)
    ADT+docetaxel8 (2.8)
    ADT+enzalutamide7 (2.5)
    ADT+cyproterone acetate3 (1.1)
    No treatment received38 (13.5)
    2nd-line treatment
    ADT+abiraterone34 (12.1)
    ADT+enzalutamide33 (11.7)
    ADT+bicalutamide14 (5.0)
    ADT+docetaxel11 (3.9)
    ADT alone5 (1.8)
    ADT+apalutamide1 (0.4)
    ADT+cabazitaxel1(0.4)
    No treatment received143 (50.8)
    3rd-line treatment
    No treatment received186 (66.0)
    ADT+abiraterone20 (7.1)
    ADT+enzalutamide14 (5.0)
    ADT+docetaxel11 (3.9)
    ADT alone4 (1.4)

    • Values are presented as numbers and percentages (%).

    • ADT: androgen deprivation therapy

  • Table 3

    - Outcome characteristics.

    Variablesn (%)
    Status of the last contact
    Alive167 (59.2)
    Dead115 (40.8)
    Length of stay in years, mean ± SD2.52±1.99
    Length of stay in years, median (min-max)2 (0-10)

    • Values are presented as numbers and percentages (%).

    • SD: standard deviation, min: minimum, max: maximum

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords